Search
Returning search results with filters:
Remove filter for
Audience: Healthcare
Remove filter for
Category: Health product
Remove filter for
Issue: COVID
Remove filter for
Issue: Health products
Clear all
Type
Audience
Category
Issue
Last updated
Recall class
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.
Displaying 1 - 15 of 97 items.
A new presentation of SPIKEVAX (elasomeran) with a concentration of 0.10 mg/mL in a 2.5 mL multidose vial was authorized on June 01, 2022. In order to provide rapid access to the new presentation of SPIKEVAX (0.10 mg/mL, 2.5 mL multidose vial), Moderna…
AlertHealth professional risk communication | 2022-06-06
The affected lots may contain an acetaldehyde concentration that is outside the acceptable limit.
RecallHealth product recall | 2022-04-21
Sotrovimab, 500 mg IV, is unlikely to maintain efficacy against the Omicron BA.2 subvariant. Sotrovimab demonstrates reduced in vitro neutralization against the Omicron BA.2 subvariant.
Audience
Healthcare professionals responsible…
AlertHealth professional risk communication | 2022-04-14
EVUSHELD (tixagevimab and cilgavimab for injection) was authorized by Health Canada on April 14, 2022. In order to provide rapid access to EVUSHELD in the context of the global COVID-19 pandemic, AstraZeneca will distribute product vials and cartons with…
AlertHealth professional risk communication | 2022-04-14
NUVAXOVID was authorized by Health Canada on February 17, 2022. In order to provide earlier access to NUVAXOVID in the context of the global pandemic, Novavax, Inc. will distribute product vials, cartons and package inserts that are in English only for a…
AlertHealth professional risk communication | 2022-02-23
Affected lot(s) may be missing risk statements and the non medicinal ingredient carbomer on the outer label.
RecallHealth product recall | 2022-02-23
The affected lots may contain an acetaldehyde concentration that is outside the acceptable limit.
RecallHealth product recall | 2022-02-08
The affected lots may contain an acetaldehyde concentration that is outside the acceptable limit.
RecallHealth product recall | 2022-02-08
UPDATED INFORMATION - July 6, 2022
A new PAXLOVID dose pack for use in patients with moderate renal impairment (eGFR ≥30 to <60 mL/min) is now available with a distinct DIN: 02527804. Pfizer has introduced this new packaging configuration to…
AlertHealth professional risk communication | 2022-01-17
There is a high risk of treatment failure with the casirivimab and imdevimab combination based on analysis of neutralization activity against selected mutations of the SARS-CoV-2 Omicron variant. The Canadian Product Monograph for casirivimab and…
AlertHealth professional risk communication | 2022-01-07
Authorization of Sotrovimab for Injection for Use in Relation to the COVID-19 Pandemic
Starting date:
September 22, 2021
Posting date:
October 4, 2021
Type of communication:…
AlertHealth professional risk communication | 2021-10-04
Graphene face masks
Starting date:
July 13, 2021
Posting date:
September 28, 2021
Type of communication:
Advisory
Subcategory:
Medical Device
Source of recall:
Health Canada…
AlertPublic advisory | 2021-09-28
NIAGARA 75% ALCOHOL ANTIBACTERIAL WIPES(2021-07-05)
Starting date:
July 5, 2021
Type of communication:
Drug Recall
Subcategory:
Natural health products
Hazard classification:…
RecallHealth product recall | 2021-07-05
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
Starting date:
June 29, 2021
Posting date:
June 29, 2021
Type of communication:
Dear Healthcare…
AlertHealth professional risk communication | 2021-06-29
LUXE HEALTH HAND SANITIZER GEL (2021-06-21)
Starting date:
June 21, 2021
Type of communication:
Drug Recall
Subcategory:
Natural health products
Hazard classification:
Type II…
RecallHealth product recall | 2021-06-21